Naziris Nikolaos, Demetzos Costas
Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Adv Exp Med Biol. 2023;1425:575-589. doi: 10.1007/978-3-031-31986-0_56.
Herein we present the modern issue of new health technologies that emerge in Medicine and Therapeutics, with regard to their development, regulatory framework, approval, and post-approval monitoring. The European law and legislation distinguish the various subcategories of health technologies in medicinal products, medical devices, biotechnological products, advanced therapy medicinal products, and nanomedicinal products. Each of these categories presents its own distinctive characteristics, based on principles that regard the development technology and intended therapeutic use, and, as a result, is defined by a unique regulatory framework inside the European legislation environment. New health technologies are a key of twenty-first-century knowledge, science, and economy and a part of society growth and economic development, while at the same time they present significant challenges, mainly through matters that regard their safety, efficacy, and value for the public. In this environment, the concept of complexity of living and artificial systems arises, as part of their nature, but also as a perspective that will give answers regarding their dynamic behavior, evolution, and overall quality.
在此,我们阐述医学与治疗领域中出现的新型健康技术的现代问题,涉及它们的发展、监管框架、审批及审批后监测。欧洲法律和法规区分了医药产品、医疗器械、生物技术产品、先进治疗医药产品和纳米医药产品等健康技术的各个子类别。基于涉及开发技术和预期治疗用途的原则,这些类别中的每一类都有其独特的特征,因此,在欧洲立法环境中由独特的监管框架进行界定。新型健康技术是21世纪知识、科学和经济的关键,也是社会发展和经济发展的一部分,同时它们也带来了重大挑战,主要体现在涉及其安全性、有效性和对公众的价值等问题上。在这种环境下,生活和人工系统的复杂性概念应运而生,这既是其本质的一部分,也是一种视角,将为其动态行为、演变和整体质量提供答案。